Monoclonal antibody targeting of anti-cancer agents: Mühlbock memorial lecture

Application of human pancreatic carcinoid BON cells for receptor-targeted drug development

“……”

Application of human pancreatic carcinoid BON cells for receptor-targeted drug development

“……”

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors

“…The idea of 'magic bullets' made a major impact on medicine and chemistry, but remained essentially unexplored for many decades. With the advent of monoclonal antibodies (5) which recognize antigens associated with many types of human cancer, important advances in targeted therapy were made (6,7). The 'magic bullet' approach was used for the construction of monoclonal antibody-toxin conjugates called immunotoxins and other chimeric toxins (7)(8)(9).…”

“…Similarly, doxorubicin (DOX) and other chemotherapeutic agents can also be conjugated to monoclonal antibodies which recognize antigens expressed on human cancers or to growth factors (11). Thus, it is now well established that chemotherapeutic compounds and toxins can be covalently attached to various carriers, including hormones, for which receptors are present on cancer cells or to antibodies that preferentially recognize tumor cells (6)(7)(8)(9)(10)(11)(12). Such conjugates are designed to deliver cytotoxic agents more selectively to cancer cells.…”

Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA

“…These include their use in immunodiagnostic tests Offprint requests to: M. R. Price for circulating antigen and for localization of tumors in patients using radiolabeled antibodies [2,13]. Their application as vehicles to target therapeutic agents (cytotoxic drugs, toxins) to the site of the tumor [1] will also be enhanced if antibodies can be selected not only on the basis of their immunoglobulin (Ig) class or subclass, but also with regard to their specificity for CEA, their reactivity with tumor cell surface-expressed CEA molecules, and whether their epitopes are repeated on the CEA molecule. Finally, for the formulation of 'cocktails' of anti-CEA antibodies for such clinical programs, it is important to select individual antibodies that are additive rather than competitive or inhibitory in their binding to CEA.…”

Application of human pancreatic carcinoid BON cells for receptor-targeted drug development

“……”

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors

“…The idea of 'magic bullets' made a major impact on medicine and chemistry, but remained essentially unexplored for many decades. With the advent of monoclonal antibodies (5) which recognize antigens associated with many types of human cancer, important advances in targeted therapy were made (6,7). The 'magic bullet' approach was used for the construction of monoclonal antibody-toxin conjugates called immunotoxins and other chimeric toxins (7)(8)(9).…”

“…Similarly, doxorubicin (DOX) and other chemotherapeutic agents can also be conjugated to monoclonal antibodies which recognize antigens expressed on human cancers or to growth factors (11). Thus, it is now well established that chemotherapeutic compounds and toxins can be covalently attached to various carriers, including hormones, for which receptors are present on cancer cells or to antibodies that preferentially recognize tumor cells (6)(7)(8)(9)(10)(11)(12). Such conjugates are designed to deliver cytotoxic agents more selectively to cancer cells.…”

Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA

“…These include their use in immunodiagnostic tests Offprint requests to: M. R. Price for circulating antigen and for localization of tumors in patients using radiolabeled antibodies [2,13]. Their application as vehicles to target therapeutic agents (cytotoxic drugs, toxins) to the site of the tumor [1] will also be enhanced if antibodies can be selected not only on the basis of their immunoglobulin (Ig) class or subclass, but also with regard to their specificity for CEA, their reactivity with tumor cell surface-expressed CEA molecules, and whether their epitopes are repeated on the CEA molecule. Finally, for the formulation of 'cocktails' of anti-CEA antibodies for such clinical programs, it is important to select individual antibodies that are additive rather than competitive or inhibitory in their binding to CEA.…”

Application of human pancreatic carcinoid BON cells for receptor-targeted drug development

“……”

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors

“…The idea of 'magic bullets' made a major impact on medicine and chemistry, but remained essentially unexplored for many decades. With the advent of monoclonal antibodies (5) which recognize antigens associated with many types of human cancer, important advances in targeted therapy were made (6,7). The 'magic bullet' approach was used for the construction of monoclonal antibody-toxin conjugates called immunotoxins and other chimeric toxins (7)(8)(9).…”

“…Similarly, doxorubicin (DOX) and other chemotherapeutic agents can also be conjugated to monoclonal antibodies which recognize antigens expressed on human cancers or to growth factors (11). Thus, it is now well established that chemotherapeutic compounds and toxins can be covalently attached to various carriers, including hormones, for which receptors are present on cancer cells or to antibodies that preferentially recognize tumor cells (6)(7)(8)(9)(10)(11)(12). Such conjugates are designed to deliver cytotoxic agents more selectively to cancer cells.…”

Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA

“…These include their use in immunodiagnostic tests Offprint requests to: M. R. Price for circulating antigen and for localization of tumors in patients using radiolabeled antibodies [2,13]. Their application as vehicles to target therapeutic agents (cytotoxic drugs, toxins) to the site of the tumor [1] will also be enhanced if antibodies can be selected not only on the basis of their immunoglobulin (Ig) class or subclass, but also with regard to their specificity for CEA, their reactivity with tumor cell surface-expressed CEA molecules, and whether their epitopes are repeated on the CEA molecule. Finally, for the formulation of 'cocktails' of anti-CEA antibodies for such clinical programs, it is important to select individual antibodies that are additive rather than competitive or inhibitory in their binding to CEA.…”